ACRS VS CARA Stock Comparison
Performance
ACRS10/100
10/100
ACRS returned -96.22% in the last 12 months. Based on SPY's performance of -11.17%, its performance is below average giving it a score of 10 of 100.
CARA10/100
10/100
CARA returned -89.02% in the last 12 months. Based on SPY's performance of -20.58%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
ACRS92/100
92/100
6 analysts offer 12-month price targets for ACRS. Together, they have an average target of 25, the most optimistic target put ACRS at 25 within 12-months and the most pessimistic has ACRS at 25.
CARA79/100
79/100
7 analysts offer 12-month price targets for CARA. Together, they have an average target of 28, the most optimistic target put CARA at 30 within 12-months and the most pessimistic has CARA at 26.
Sentiment
ACRS69/100
69/100
ACRS had a bullish sentiment score of 68.61% across Twitter and StockTwits over the last 12 months. It had an average of 32.27 posts, 12.68 comments, and 65.86 likes per day.
CARA67/100
67/100
CARA had a bullish sentiment score of 67.18% across Twitter and StockTwits over the last 12 months. It had an average of 7.42 posts, 3.60 comments, and 9.03 likes per day.
Technicals
ACRS14/100
14/100
ACRS receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
CARA14/100
14/100
CARA receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
Earnings
ACRS10/100
10/100
ACRS has missed earnings 8 times in the last 20 quarters.
CARA10/100
10/100
CARA has missed earnings 6 times in the last 20 quarters.
Profit
ACRS10/100
10/100
Out of the last 20 quarters, ACRS has had 0 profitable quarters and has increased their profits year over year on 0 of them.
CARA10/100
10/100
Out of the last 20 quarters, CARA has had 1 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
ACRS42/100
42/100
ACRS has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.
CARA41/100
41/100
CARA has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Aclaris Therapeutics, Inc. Summary
Nasdaq / ACRS
Healthcare
Medical - Diagnostics & Research
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Cara Therapeutics, Inc. Summary
Nasdaq / CARA
Healthcare
Biotechnology
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ACRS to other companies in the same or a similar industry.